[Worsening of leprosy lesions in a Philippine-born patient].
Ramos
Antonio
A
Servicio de Medicina Interna III, Hospital Universitario Puerta de Hierro, Universidad Autónoma de Madrid, Madrid, España. antrammar@yahoo.es
Roustán
Gastón
G
Angel-Moreno
Alfonso
A
Suárez
Emilio
E
D000328:Adult; D000942:Antigens, Bacterial / Q000276:immunology; D003622:Dapsone / Q000009:adverse effects* / Q000627:therapeutic use; D005148:Facial Dermatoses / Q000139:chemically induced / Q000188:drug therapy; D005334:Fever / Q000139:chemically induced; D006801:Humans; D007917:Leprostatic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D015439:Leprosy, Borderline / Q000188:drug therapy / Q000503:physiopathology*; D008297:Male; D009166:Mycobacterium leprae / Q000276:immunology; D010523:Peripheral Nervous System Diseases / Q000209:etiology; D010679:Philippines / Q000208:ethnology; D011241:Prednisone / Q000627:therapeutic use; D012293:Rifampin / Q000009:adverse effects* / Q000627:therapeutic use; D014605:Uveitis / Q000139:chemically induced / Q000276:immunology
D000942:Antigens, Bacterial; D007917:Leprostatic Agents; D003622:Dapsone; D011241:Prednisone; D012293:Rifampin